Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...